Core Viewpoint - The company, Jiuzhitang, has reported a significant decline in net profit attributable to shareholders, primarily due to a decrease in operating income and an increase in expense ratios, while also announcing a strategic investment in Harbin Jixianglong Biotechnology Co., Ltd. to enhance its business layout in the pharmaceutical industry [3][11][15]. Financial Performance - The net profit attributable to shareholders, excluding non-recurring gains and losses, decreased by 118.77% compared to the same period last year, attributed to a decline in operating income, increased expense ratios, and reduced investment income [3]. - The net cash flow from operating activities increased by 527.78% year-to-date compared to the same period last year, mainly due to improved collection efforts and reduced cash payments for goods and services [3]. Investment Overview - Jiuzhitang signed an investment agreement to acquire a 51.6667% stake in Harbin Jixianglong Biotechnology Co., Ltd. for a total consideration of RMB 31 million, which includes RMB 21 million for existing shares and RMB 10 million for new capital [11][15][55]. - The investment aims to enhance Jiuzhitang's capabilities in drug production, research and development, and related industries, thereby improving its overall competitive strength [15]. Company Background - Harbin Jixianglong is a national high-tech enterprise specializing in the research, production, and technical services of peptide drugs, with over ten years of experience in the peptide industry [24][25]. - The company has developed a strong competitive advantage through its proprietary technologies and has received multiple production approvals for its peptide raw materials [28][32]. Financial Valuation - The valuation of Harbin Jixianglong was assessed using both the income approach and market approach, with the income approach yielding a valuation of RMB 54.81 million, reflecting a significant increase from its book value [49][50]. - The agreed transaction price for the equity transfer was based on this valuation, with the total consideration set at RMB 31 million [55].